Celltrion Wins Global First Approval For High-Concentration Humira Biosimilar

Yuflyma 100mg/ml Version Of Adalimumab Ready For Launch In Europe

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Celltrion has received a pan-European marketing authorization for its Yuflyma high-concentration adalimumab biosimilar, making it the first firm worldwide to register a 100mg/ml rival to the blockbuster Humira brand.

Two Weight Lifters Silhouette
Celltrion has the first higher-strength adalimumab biosimilar • Source: Shutterstock

Celltrion has achieved a global first after receiving a marketing authorization for a 100mg/ml biosimilar version of Humira (adalimumab). The European Commission’s pan-European approval follows a positive opinion for the CT-P17 candidate granted by the European Medicines Agency’s Committee for Medicinal Products for Human Use late last year. (Also see "Celltrion Wins Race For High-Concentration Adalimumab" - Generics Bulletin, 11 December, 2020.)

Yuflyma – which will be available as 40mg solution for injection in a pre-filled syringe and pre-filled pen – has...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.